Careers in Israel
Careers in USA
Board of Directors
Scientific Advisory Board
Johns Hopkins University
Mount Sinai Hospital
Annual and Quarterly Reports
pioneer in computational drug target discovery
Innovative immuno-oncology pipeline
Jul 16, 2019
Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody
Jul 02, 2019
Compugen Appoints Eran Perry to its Board of Directors
Research and Development
Our optimized process for predictive discovery of novel drug targets
Our ongoing Phase 1 study of COM701, a first-in-class antibody targeting PVRIG, a novel ICP target
Compugen, FROM CODE TO CURE
COM701 is a first-in-class therapeutic antibody targeting PVRIG, a novel immune checkpoint target candidate discovered computationally by Compugen.
BAY 1905254/ILDR2 (partnered)
ILDR2 (formerly CGEN-15001T) is a novel immune checkpoint target discovered by Compugen and partnered to Bayer.
COM902, an anti-TIGIT inhibitor, is being developed as an integral component of the COM701 program, to facilitate the combination strategy for COM701.
COM902 is being developed as an integral component of the COM701 program, to provide the company with an internally-developed antibody to facilitate the combination strategy for COM701
Multiple myeloid programs
Compugen’s early stage programs are focused largely on myeloid targets addressing a range of mechanisms of action.
Jun 04, 2019
Compugen Presentation at the Jefferies 2019 Healthcare Conference
New York, NY
May 20, 2019
Compugen First Quarter 2019 Conference Call
Jun 01, 2019
COM701 Phase 1 Study Trial-in-Progress Poster Presentation, ASCO 2019 Annual Meeting
Click here for more info about partnering with Compugen